勾引
发表于 2025-3-25 05:41:01
https://doi.org/10.1007/978-3-7091-7494-4Alzheimer; Parkinson; diagnosis; dopamine; psychiatric disorder
Rejuvenate
发表于 2025-3-25 08:26:15
978-3-211-82891-5Springer-Verlag/Wien 1996
稀释前
发表于 2025-3-25 14:35:23
Journal of Neural Transmission. Supplementahttp://image.papertrans.cn/d/image/265790.jpg
松果
发表于 2025-3-25 16:39:15
http://reply.papertrans.cn/27/2658/265790/265790_24.png
Gratuitous
发表于 2025-3-25 22:33:36
http://reply.papertrans.cn/27/2658/265790/265790_25.png
Habituate
发表于 2025-3-26 02:06:49
http://reply.papertrans.cn/27/2658/265790/265790_26.png
moribund
发表于 2025-3-26 07:45:49
,The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (−)-deprenyl reseaplex mechanism. The MAO-B inhibition could result in a potentiation of the effect and the reduction of the dose of L-dopa, including the restoration of the sensitivity to L-dopa treatment, when the response to the drug has already been diminished or lost. Pre-treatment with (−)deprenyl prevent the e
aneurysm
发表于 2025-3-26 08:38:38
http://reply.papertrans.cn/27/2658/265790/265790_28.png
magnanimity
发表于 2025-3-26 13:04:11
http://reply.papertrans.cn/27/2658/265790/265790_29.png
缩短
发表于 2025-3-26 16:52:50
,Deprenyl in the treatment of Parkinson’s disease: clinical effects and speculations on mechanism ofputative neuroprotective therapy. Clinical trials demonstrate that selegiline slows the rate of disease progression and delays the appearance of disability necessitating levodopa. However, confounding symptomatic effects have made it difficult to ascertain the presence of any direct neuroprotective